Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.

[1]  Per Magne Ueland,et al.  Homocysteine lowering and cardiovascular events after acute myocardial infarction. , 2006, The New England journal of medicine.

[2]  S. Yusuf,et al.  Homocysteine lowering with folic acid and B vitamins in vascular disease. , 2006, The New England journal of medicine.

[3]  Raimund Erbel,et al.  Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. , 2006, JAMA.

[4]  R. Krauss,et al.  Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel , 2006, Journal of internal medicine.

[5]  P. Sorlie,et al.  Trends in Serum Lipids and Lipoproteins of Adults 1960-2002 , 2006 .

[6]  Ralph B D'Agostino,et al.  Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age , 2006, Circulation.

[7]  J. Manson,et al.  Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. , 2006, JAMA.

[8]  Walter C Willett,et al.  Obesity as Compared With Physical Activity in Predicting Risk of Coronary Heart Disease in Women , 2006, Circulation.

[9]  Peter T Katzmarzyk,et al.  Prevalence of class I, II and III obesity in Canada , 2006, Canadian Medical Association Journal.

[10]  A. Dyer,et al.  Midlife body mass index and hospitalization and mortality in older age. , 2006, JAMA.

[11]  J. Manson,et al.  Use of a dummy (pacifier) during sleep and risk of sudden infant death syndrome (SIDS): population based case-control study , 2005, BMJ : British Medical Journal.

[12]  E. Fishman,et al.  Women with a low Framingham risk score and a family history of premature coronary heart disease have a high prevalence of subclinical coronary atherosclerosis. , 2005, American heart journal.

[13]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[14]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[15]  P. Macfarlane,et al.  Plasma Lipoproteins and Apolipoproteins as Predictors of Cardiovascular Risk and Treatment Benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) , 2005, Circulation.

[16]  S. Yusuf,et al.  Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study , 2005, The Lancet.

[17]  D. Berman,et al.  Prognostic significance of dyspnea in patients referred for cardiac stress testing. , 2005, The New England journal of medicine.

[18]  J. Rindone,et al.  Experience with statin use in patients with chronic hepatitis C infection. , 2005, The American journal of cardiology.

[19]  M. Pfeffer,et al.  Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. , 2005, Journal of the American College of Cardiology.

[20]  L. Kuller,et al.  C-reactive protein, heart disease risk, and the popular media. , 2005, Archives of internal medicine.

[21]  M. Zhan,et al.  High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. , 2005, Archives of internal medicine.

[22]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[23]  R. Collins,et al.  Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). , 2005, Diabetes care.

[24]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[25]  R. Blumenthal,et al.  Low HDL Cholesterol Levels , 2005 .

[26]  A. Folsom,et al.  Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. , 2005, Archives of internal medicine.

[27]  B. Howard,et al.  C-Reactive Protein as a Predictor of Cardiovascular Risk in a Population With a High Prevalence of Diabetes: The Strong Heart Study , 2005, Circulation.

[28]  J. Critchley,et al.  Modelling the decline in coronary heart disease deaths in England and Wales, 1981-2000: comparing contributions from primary prevention and secondary prevention , 2005, BMJ : British Medical Journal.

[29]  J. Jukema,et al.  No Effect of C-Reactive Protein on Early Atherosclerosis Development in Apolipoprotein E*3-Leiden/Human C-Reactive Protein Transgenic Mice , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[30]  N. Cook,et al.  Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. , 2005, JAMA.

[31]  J. Polak,et al.  C-Reactive Protein and the 10-Year Incidence of Coronary Heart Disease in Older Men and Women: The Cardiovascular Health Study , 2005, Circulation.

[32]  J. Sundquist,et al.  The long-term effect of physical activity on incidence of coronary heart disease: a 12-year follow-up study. , 2005, Preventive medicine.

[33]  C. Sabin,et al.  Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Yusuf,et al.  Ethnic differences in the relationships between obesity and glucose-metabolic abnormalities: a cross-sectional population-based study , 2005, International Journal of Obesity.

[35]  P. Steinbigler,et al.  Multislice spiral computed tomographic angiography of coronary arteries in patients with suspected coronary artery disease: an effective filter before catheter angiography? , 2005, American heart journal.

[36]  Andrew Briggs,et al.  Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20 536 individuals , 2005, The Lancet.

[37]  C. Byrne,et al.  Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[38]  R. McPherson,et al.  The analysis by Manuel and colleagues creates controversy with headlines, not data , 2005, Canadian Medical Association Journal.

[39]  A. Laupacis,et al.  The 2003 Canadian recommendations for dyslipidemia management: Revisions are needed , 2005, Canadian Medical Association Journal.

[40]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[41]  N. Chalasani.  Statins and hepatotoxicity: Focus on patients with fatty liver , 2005, Hepatology.

[42]  M. Budoff,et al.  Relation of family history of premature coronary heart disease and metabolic risk factors to risk of coronary arterial calcium in asymptomatic subjects. , 2005, The American journal of cardiology.

[43]  M. Buxton,et al.  Cost-Effectiveness of Atorvastatin for the Prevention of Coronary and Stroke Events: An Economic Analysis of the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA) , 2005 .

[44]  Jeannie K. Lee,et al.  Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins , 2004, Circulation.

[45]  Gareth Ambler,et al.  Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory? , 2004, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[46]  Richard Platt,et al.  Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. , 2004, JAMA.

[47]  Steven Hawken,et al.  Preventive cardiologyAbstractsEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study , 2004 .

[48]  A. Yashin,et al.  Genetic Influences on CHD-Death and the Impact of Known Risk Factors: Comparison of Two Frailty Models , 2004, Behavior genetics.

[49]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[50]  N. Day,et al.  Association of Hemoglobin A1c with Cardiovascular Disease and Mortality in Adults: The European Prospective Investigation into Cancer in Norfolk , 2004, Annals of Internal Medicine.

[51]  Neil R. Powe,et al.  Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus , 2004, Annals of Internal Medicine.

[52]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[53]  Ralph B D'Agostino,et al.  Framingham risk score and prediction of lifetime risk for coronary heart disease. , 2004, The American journal of cardiology.

[54]  Dong Zhao,et al.  Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. , 2004, JAMA.

[55]  O. Carbonara,et al.  Glucose metabolism and coronary heart disease in patients with normal glucose tolerance , 2004 .

[56]  Ralph B D'Agostino,et al.  Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands , 2004, BMJ : British Medical Journal.

[57]  E. Tai,et al.  Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? , 2004, Diabetes care.

[58]  N. Cook,et al.  Clinical Usefulness of Very High and Very Low Levels of C-Reactive Protein Across the Full Range of Framingham Risk Scores , 2004, Circulation.

[59]  J. Manson,et al.  Hemoglobin A1c level and future cardiovascular events among women. , 2004, Archives of Internal Medicine.

[60]  J. Frohlich,et al.  Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. , 2004, The American journal of cardiology.

[61]  Paul Schoenhagen,et al.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.

[62]  B. G. Brown,et al.  Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). , 2004, The American journal of cardiology.

[63]  R. Detrano,et al.  Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. , 2004, JAMA.

[64]  J. Brunzell,et al.  Varying Cost and Free Nicotinic Acid Content in Over-the-Counter Niacin Preparations for Dyslipidemia , 2003, Annals of Internal Medicine.

[65]  Shah Ebrahim,et al.  JOINT ESC GUIDELINES 2016 European Guidelines on cardiovascular disease prevention in clinical practice – Web Addenda , 2016 .

[66]  A. Dyer,et al.  Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. , 2003, JAMA.

[67]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[68]  R. McPherson,et al.  Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[69]  Ronald A. Thisted,et al.  Exercise Capacity and the Risk of Death in Women: The St James Women Take Heart Project , 2003, Circulation.

[70]  D. Levy,et al.  Lifetime risk of coronary heart disease by cholesterol levels at selected ages. , 2003, Archives of internal medicine.

[71]  M. Ward,et al.  Hospitalizations for coronary artery disease among patients with systemic lupus erythematosus. , 2003, Arthritis and rheumatism.

[72]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2003 .

[73]  Paul M Ridker,et al.  High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. , 2003, The American journal of cardiology.

[74]  A. Dyer,et al.  Major Risk Factors as Antecedents of Fatal and Nonfatal Coronary Heart Disease Events , 2003 .

[75]  Eric J Topol,et al.  Prevalence of conventional risk factors in patients with coronary heart disease. , 2003, JAMA.

[76]  P. Greenland,et al.  Clinical practice. Selecting asymptomatic patients for coronary computed tomography or electrocardiographic exercise testing. , 2003, The New England journal of medicine.

[77]  S. Yusuf,et al.  Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease , 2003, Circulation.

[78]  J. Critchley,et al.  Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. , 2003, JAMA.

[79]  N. Poulter,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial☆ , 2003 .

[80]  N J Wald,et al.  Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis , 2003, BMJ : British Medical Journal.

[81]  Fernando Costa,et al.  Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Ph , 2003, Circulation.

[82]  P. Greenland,et al.  Impact of minor electrocardiographic ST-segment and/or T-wave abnormalities on cardiovascular mortality during long-term follow-up. , 2003, The American journal of cardiology.

[83]  S. Teutsch,et al.  NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. , 2003, Diabetes.

[84]  Nancy R Cook,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.

[85]  Daniel Levy,et al.  Long-term trends in the incidence of and survival with heart failure. , 2002, The New England journal of medicine.

[86]  Walter C Willett,et al.  Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. , 2002, Diabetes care.

[87]  J. Strong,et al.  Obesity Accelerates the Progression of Coronary Atherosclerosis in Young Men , 2002, Circulation.

[88]  A. Chait,et al.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease☆ , 2002 .

[89]  V. Armstrong,et al.  Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. , 2002, Journal of hepatology.

[90]  GerdAssmann,et al.  Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study , 2002 .

[91]  R. Holman,et al.  The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). , 2001, Clinical science.

[92]  A. Adler.  Cardiovascular risk reduction in diabetes: underemphasised and overdue. Messages from major trials. , 2001, Clinical medicine.

[93]  S M Grundy,et al.  Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. , 2001, Circulation.

[94]  A. Hofman,et al.  Is Carotid Intima-Media Thickness Useful in Cardiovascular Disease Risk Assessment?: The Rotterdam Study , 2001, Stroke.

[95]  R. Fagard.  Exercise characteristics and the blood pressure response to dynamic physical training. , 2001, Medicine and science in sports and exercise.

[96]  O. Devuyst,et al.  Deterioration in renal function associated with fibrate therapy. , 2001, Clinical nephrology.

[97]  A. Ahlbom,et al.  Family History of Coronary Heart Disease, a Strong Risk Factor for Myocardial Infarction Interacting with Other Cardiovascular Risk Factors: Results from the Stockholm Heart Epidemiology Program (SHEEP) , 2001, Epidemiology.

[98]  N. Wareham,et al.  Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk) , 2001, BMJ : British Medical Journal.

[99]  R. McPherson,et al.  Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[100]  J. Danesh,et al.  Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies , 2000, Circulation.

[101]  S. Blair,et al.  Maximal exercise test as a predictor of risk for mortality from coronary heart disease in asymptomatic men. , 2000, The American journal of cardiology.

[102]  R N Bergman,et al.  Carotid artery atherosclerosis in type-2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease (The Insulin Resistance Atherosclerosis Study). , 2000, The American journal of cardiology.

[103]  D R Shapiro,et al.  Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). , 2000, Circulation.

[104]  M. de Lorgeril,et al.  Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. , 1999, Circulation.

[105]  Enrique Sanchez-Delgado,et al.  Lifetime risk of developing coronary heart disease , 1999, The Lancet.

[106]  R. Kronmal,et al.  Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. , 1999, The New England journal of medicine.

[107]  I. Borecki,et al.  Lipoprotein(a) interactions with lipid and non-lipid risk factors in patients with early onset coronary artery disease: results from the NHLBI Family Heart Study. , 1998, Atherosclerosis.

[108]  P. Passa,et al.  [Cardiovascular risk and diabetes]. , 1998, Annales d'endocrinologie.

[109]  W L Haskell,et al.  Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. , 1998, The New England journal of medicine.

[110]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[111]  Beverley Balkau,et al.  High Blood Glucose Concentration Is a Risk Factor for Mortality in Middle-Aged Nondiabetic Men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study , 1998, Diabetes Care.

[112]  R. McPherson,et al.  Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. , 1998, The American journal of cardiology.

[113]  B M Psaty,et al.  Family history as a risk factor for primary cardiac arrest. , 1998, Circulation.

[114]  S. Hunt,et al.  Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[115]  C. Sempos,et al.  Consistency between US dietary fat intake and serum total cholesterol concentrations: the National Health and Nutrition Examination Surveys. , 1997, The American journal of clinical nutrition.

[116]  L. Goldman,et al.  The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. , 1997, JAMA.

[117]  G. Dagenais,et al.  Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. , 1997, Circulation.

[118]  P. Macfarlane,et al.  West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996 .

[119]  G. Dagenais,et al.  Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study. , 1996, Circulation.

[120]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[121]  G. Omenn,et al.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. , 1995, JAMA.

[122]  L. Coupal,et al.  Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? , 1995, JAMA.

[123]  P. Wilson,et al.  A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. , 1994, Circulation.

[124]  L. Berkman,et al.  Genetic susceptibility to death from coronary heart disease in a study of twins. , 1994, The New England journal of medicine.

[125]  J. D. Proctor,et al.  A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. , 1994, JAMA.

[126]  P. Ridker,et al.  A prospective study of lipoprotein(a) and the risk of myocardial infarction. , 1993, JAMA.

[127]  B. Lewis,et al.  Effects on Coronary Artery Disease of Lipid-Lowering Diet, or Diet Plus Cholestyramine, in the St. Thomasʼ Artherosclerosis Regression Study (STARS) , 1992 .

[128]  G. Watts,et al.  Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS) , 1992, The Lancet.

[129]  J. Cutler,et al.  Prognostic value of exercise electrocardiogram in men at high risk of future coronary heart disease: Multiple Risk Factor Intervention Trial experience. , 1986, Journal of the American College of Cardiology.

[130]  K. Maurer,et al.  Third national health and nutrition examination survey , 1985 .

[131]  I. Holme,et al.  EFFECT OF DIET AND SMOKING INTERVENTION ON THE INCIDENCE OF CORONARY HEART DISEASE Report from the Oslo Study Group of a Randomised Trial in Healthy Men , 1981, The Lancet.

[132]  I. Hjermann,et al.  EFFECT OF DIET AND SMOKING INTERVENTION ON THE INCIDENCE OF CORONARY HEART DISEASE , 1981 .

[133]  James B Metcalfe,et al.  Moving forward. , 2008, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[134]  J. Tsai,et al.  Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. , 2006, The American journal of cardiology.

[135]  D. Coplen.  Erectile Dysfunction and Subsequent Cardiovascular Disease , 2006 .

[136]  W. Frishman,et al.  Noninvasive Coronary Angiography With Multislice Computed Tomography , 2006 .

[137]  J. Chalmers.  Messages from major trials , 2006 .

[138]  R. Blumenthal,et al.  Clinical practice. Low HDL cholesterol levels. , 2005, The New England journal of medicine.

[139]  T. Marwick,et al.  The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[140]  S. Mora,et al.  Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study , 2004 .

[141]  J. LeLorier,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[142]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002, The New England journal of medicine.

[143]  S. Grundy,et al.  ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. , 2002, Stroke.

[144]  Loyd,et al.  SIMVASTATIN AND NIACIN , ANTIOXIDANT VITAMINS , OR THE COMBINATION FOR THE PREVENTION OF CORONARY DISEASE , 2001 .

[145]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[146]  Eary,et al.  CAROTID-ARTERY INTIMA AND MEDIA THICKNESS AS A RISK FACTOR FOR MYOCARDIAL INFARCTION AND STROKE IN OLDER ADULTS , 2000 .

[147]  S. Yusuf,et al.  Differences in risk factors, atherosclerosis and cardiovascular disease between ethnic groups in Canada: the study of health assessment and risk in ethnic groups (SHARE). , 2000, Indian heart journal.

[148]  M. Moore.  Fasting insulin and apolipoprotein B levels and low density lipoprotein particle size as risk factors for ischemic heart disease. , 1998, Journal of insurance medicine.

[149]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.

[150]  H. Ford,et al.  Moving Forward , 1930 .